Elevance Health Stock at $320 With a $388 Street Mean Target: Here’s What the Numbers Say

Elevance Health (ELV) stock is currently trading at $320, significantly below its 52-week high, despite management reaffirming its 2026 adjusted EPS guidance of at least $25.50. The company is strategically repositioning itself from a traditional health insurer to a diversified health services platform, driven by the growth of its Carelon segments. Wall Street analysts maintain a strong conviction with a mean price target of $387.9, implying a 21.2% upside, and TIKR’s valuation model suggests a 35.7% total return by December 2030, indicating the stock may be undervalued.